Catalogue Number: AB05114-10.29-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | LCMV surface GP; lineage I Lassa fever virus; lineage I LASV; LASV; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2; 18.5C-M28 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug |
| Host name: | Human |
| Clone: | M28 |
| Isotype: | |
| Immunogen: | The original antibody was generated by introducing two mutations (S32R and R55 insertion) into the sequence of the parent clone 18.5C (an isolate from a human survivor of Lassa fever). |
| Application: | ELISA, EM, NT, InVitroA, InVivoA |
Purified
P07399
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
The original antibody (human IgG1) was generated and confirmed to specifically recognize the target via ELISA. A Fab version of it was generated and tested for neutralization. This antibody demonstrated potent in vitro neutralization (IC₅₀ ~ 0.51 µg/mL) and both prophylactic and therapeutic efficacy in a murine chronic LCMV model, with complete viral clearance and protection from weight loss. Furthermore, this antibody enabled high-resolution cryoEM of the LCMV GP trimer in both apo and Fab-bound states, defining a quaternary, pre-fusion-specific epitope (Moon-Walker et al., 2023; PMID: 36990092). In vitro, this antibody fully neutralized cell-free LCMV at 5 µg/mL and was used to demonstrate that ~50% of viral spread occurs via antibody-resistant, direct cell-to-cell nanotube transfer (Byford et al., 2024; PMID: 39578605).